HK1101354A1 - Levocetirizine hydrochloride formulation for external use - Google Patents
Levocetirizine hydrochloride formulation for external useInfo
- Publication number
- HK1101354A1 HK1101354A1 HK07109304.5A HK07109304A HK1101354A1 HK 1101354 A1 HK1101354 A1 HK 1101354A1 HK 07109304 A HK07109304 A HK 07109304A HK 1101354 A1 HK1101354 A1 HK 1101354A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- external use
- hydrochloride formulation
- levocetirizine hydrochloride
- levocetirizine
- formulation
- Prior art date
Links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510129203 CN1813743A (en) | 2005-11-29 | 2005-11-29 | External-use formulation of levocetirizine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1101354A1 true HK1101354A1 (en) | 2007-10-18 |
Family
ID=36906177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07109304.5A HK1101354A1 (en) | 2005-11-29 | 2007-08-27 | Levocetirizine hydrochloride formulation for external use |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1813743A (en) |
HK (1) | HK1101354A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120142704A1 (en) * | 2009-08-12 | 2012-06-07 | Lun Better Pharmaceutical Co., Ltd | Pharmaceutical solution of cetirizine hydrochloride |
CN103860462A (en) * | 2014-01-14 | 2014-06-18 | 万特制药(海南)有限公司 | Levocetirizine hydrochloride syrup and preparation method |
WO2022175829A1 (en) | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
-
2005
- 2005-11-29 CN CN 200510129203 patent/CN1813743A/en active Pending
-
2007
- 2007-08-27 HK HK07109304.5A patent/HK1101354A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1813743A (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200801773B (en) | New formulation | |
TWI370115B (en) | New formulation | |
HK1198914A1 (en) | Novel dosage formulation | |
PT3424932T (en) | Boronophthalides for therapeutic use | |
IL191287A0 (en) | Atorvastatin formulation | |
IL189781A0 (en) | Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same | |
GB0526419D0 (en) | Formulation | |
IL187510A0 (en) | Proteases for pharmaceutical use | |
GB0517673D0 (en) | Formulation | |
EP1928469A4 (en) | Fulvestrant formulation | |
EP1852106A4 (en) | Solid ophthalmic drug for external use | |
EP1938808A4 (en) | Preparation for external use | |
GB0423565D0 (en) | Formulation | |
PL1855661T3 (en) | Formulation for aviptadil | |
GB0412530D0 (en) | Formulation | |
GB0501030D0 (en) | Formulation | |
HK1101354A1 (en) | Levocetirizine hydrochloride formulation for external use | |
GB0504940D0 (en) | Vaccine formulation | |
PL1688129T3 (en) | New therapeutic formulation | |
ZA200710642B (en) | Proteases for pharmaceutical use | |
GB0522473D0 (en) | A pharmaceutical formulation | |
PT1855661E (en) | Formulation for aviptadil | |
GB0506035D0 (en) | Improved formulation | |
GB0515937D0 (en) | Pharmaceutical formulation | |
GB0500807D0 (en) | Formulation |